Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
Opus Genetics completed enrollment in Cohort 1 of its Phase 1/2 study of OPGx-BEST1, enrolling five participants across both dominant and recessive forms of BEST disease. Four participants have been dosed with the subretinal gene therapy, and the fifth is scheduled for dosing this month; topline data from the full cohort is expected in September 2026.
Key figures
- Drug Name
- OPGx-BEST1
- Phase Of Trial
- Phase 1/2
- Arb participants
- 2
- Pipeline programs
- 7
- Bvm d participants
- 3
- Cohort 1 enrollment
- 5
- Prevalence best1 irds
- 22,000 patients
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.